Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) traded down 14.5% during mid-day trading on Tuesday . The stock traded as low as C$0.27 and last traded at C$0.27. 438,482 shares were traded during mid-day trading, a decline of 36% from the average session volume of 690,023 shares. The stock had previously closed at C$0.31.
Hemostemix Stock Performance
The stock has a market capitalization of C$23.09 million, a P/E ratio of -13.25 and a beta of 0.20. The firm’s 50-day simple moving average is C$0.11 and its 200 day simple moving average is C$0.08.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- Short Selling – The Pros and Cons
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- Market Cap Calculator: How to Calculate Market Cap
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
